22 Aug FDA Approves Another Drug That Slows Cognitive Decline
In July 2024, the FDA approved Kisunla (formerly called Donanemab) which is anti-amyloid clearing treatment which slows cognitive decline by 35% (up to 60% in a separate analysis). Although the FDA rejected Eli Lilly’s request for accelerated approval of the drug in January 2023 since...